Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Nuvation Bio Inc.

Get SEC filing alerts via email and in your feed for Nuvation Bio Inc.

NUVB NUVB-WT

Nuvation Bio Inc.

About Nuvation Bio Inc.

Nuvation Bio Inc. is a biopharmaceutical company focused on developing innovative oncology therapies. Its core activities include discovering, developing, and commercializing targeted small molecules and drug conjugates for cancer treatment. The company’s pipeline features advanced candidates like taletrectinib for ROS1+ lung cancer and safusidenib for mIDH1 glioma, leveraging proprietary chemistry and strategic licensing to address unmet medical needs globally.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Nuvation Bio Inc.

1
1
Nuvation Bio Inc. Nuvation Bio Reports $83.2 Million Revenue and $5.4 Million Net Income in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Nuvation Bio Inc. Nuvation Bio Inc. Reports $62.9 Million Revenue for Fiscal Year 2025, Highlights IBTROZI Launch

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Nuvation Bio Inc. Nuvation Bio Reports $13.1 Million Revenue in Q3 2025, Despite $55.8 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Nuvation Bio Inc. Nuvation Bio Reports $4.8M Revenue in Q2 2025, Significant Decrease in Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Nuvation Bio Inc. Nuvation Bio Reports $3.1 Million Revenue in Q1 2025, Faces $53.2 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Nuvation Bio Inc. Nuvation Bio Reports $7.9 Million Revenue Growth Following AnHeart Acquisition

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Nuvation Bio Inc. Nuvation Bio Reports Financial Results for Q3 2024, Net Loss Widens Amid Increased Expenses and Research Efforts

Via official filing (AI summary) | over 1 year ago | 0 comments